Nuveen LLC Purchases New Shares in Tenaya Therapeutics, Inc. $TNYA

Key Points

• Nuveen LLC has acquired approximately 226,202 shares of Tenaya Therapeutics, Inc., valued at around $129,000, increasing its ownership stake to about 0.26% as per the latest SEC filing.
• Multiple institutional investors have shown increased interest in Tenaya Therapeutics, with firms like Deutsche Bank AG boosting their holdings by over 300% during the fourth quarter.
• Analysts are generally optimistic about Tenaya Therapeutics, with a consensus rating of "Buy" and a price target averaging around $6.25.

Nuveen LLC acquired a new position in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 226,202 shares of the company's stock, valued at approximately $129,000. Nuveen LLC owned about 0.26% of Tenaya Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in TNYA. Hsbc Holdings PLC purchased a new stake in Tenaya Therapeutics during the fourth quarter worth about $45,000. Northern Trust Corp increased its holdings in Tenaya Therapeutics by 6.2% during the fourth quarter. Northern Trust Corp now owns 472,479 shares of the company's stock worth $676,000 after buying an additional 27,632 shares during the last quarter. Deutsche Bank AG increased its holdings in Tenaya Therapeutics by 304.1% during the fourth quarter. Deutsche Bank AG now owns 129,319 shares of the company's stock worth $185,000 after buying an additional 97,318 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in Tenaya Therapeutics by 25.2% during the fourth quarter. Nuveen Asset Management LLC now owns 345,192 shares of the company's stock worth $494,000 after buying an additional 69,377 shares during the last quarter. Finally, Trustees of Columbia University in the City of New York purchased a new stake in Tenaya Therapeutics during the fourth quarter worth about $417,000. Hedge funds and other institutional investors own 90.54% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Chardan Capital restated a "buy" rating and set a $9.00 price objective on shares of Tenaya Therapeutics in a report on Thursday, August 7th. HC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Tenaya Therapeutics in a report on Tuesday, September 2nd. Finally, Wall Street Zen upgraded shares of Tenaya Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $6.25.

Tenaya Therapeutics Stock Up 8.9%

TNYA opened at $1.35 on Monday. The company has a market capitalization of $220.02 million, a price-to-earnings ratio of -1.41 and a beta of 3.06. The firm has a 50-day moving average price of $0.87 and a 200-day moving average price of $0.67. Tenaya Therapeutics, Inc. has a twelve month low of $0.36 and a twelve month high of $4.01.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.06. On average, sell-side analysts expect that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.

Want to see what other hedge funds are holding TNYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.